Option chain shows key data for Salarius Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Salarius Pharmaceuticals.

Salarius Pharmaceuticals (NASDAQ:SLRX) Stock, Option Chain

Salarius Pharmaceuticals

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

benzinga_deal_dispatch2

News

ABBV

BIIB

LNTH

NGVT

NPSCY

RVNC

SAGE

SANW

SLRX

TMUS

Deal opportunities abound: KKR &amp; Co.&#39;s stake in Maya; DuPont&#39;s electronics business; Ingevity&#39;s North Charleston site; and S&amp;W Seed Company.

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Movers

Salarius Pharmaceuticals (NASDAQ: SLRX) shares are trading higher Monday after the company announced a merger agreement with Decoy Therapeutics, a privately held biopharmaceutical company. 

Salarius Pharmaceuticals Shares Are Skyrocketing Today: What&#39;s Going On?

SPDR Gold Shares (GLD)

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CMTL

ITCI

MRNA

PHIO

Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals Inc

Press Releases

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting

Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement

Shareholder Alert: Ademi LLP investigates whether Salarius Pharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Apollomics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Entero Therapeutics

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

NuCana

Onconetix

Palisade Bio

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Scorpius Holdings

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Vincerx Pharma

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

ZyVersa Therapeutics, Inc. - Common Stock

Comments

Salarius Pharmaceuticals

Salarius Pharmaceuticals (SLRX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga